GU Cancers 2024 | KEYNOTE-676 cohort A: pembrolizumab plus BCG in recurrent HR NMIBC

Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, gives an overview of the Phase III KEYNOTE-676 trial (NCT03711032), which assesses the efficacy of pembrolizumab combined with Bacillus Calmette-Guérin (BCG) compared to BCG alone in patients with persistent/recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) after initial BCG induction. Eligible patients are randomly assigned either pembrolizumab plus BCG or BCG alone. The primary endpoint is the complete response rate in patients with carcinoma in situ (CIS), and secondary endpoints include duration of response, event-free survival, and safety. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.